Posters
Clinical outcomes of the double-needle technique for flanged intrascleral posterior chamber intraocular lens fixation
Poster Details
First Author: M.Tamenkovic SERBIA
Co Author(s): I. Sencanic V. Jaksic S. Babovic N. Nikitovic A. Bajic R. Gvozdenovic
Abstract Details
Purpose:
To report and evaluate outcomes of the double-needle technique for flanged intrascleral posterior chamber intraocular lens (IOL) fixation.
Setting:
Clinic for Eye Disease “Prof. dr Ivan Stankovic” University Medical Center “Zvezdara”.
Methods:
Aphakic eyes with absence of adequate capsular support underwent a surgical procedure of flanged intrascleral posterior chamber intraocular lens fixation, the technique that involves externalization of IOL haptics using double 30 gauge needles. A flange was created at the end of each haptic that were then fixed into the scleral tunnel and then covered with conjunctiva. Patients were followed up postoperatively and main outcome measures were monitored: best-corrected visual acuity (BCVA) converted to the logarithm of the minimum angle of resolution (logMAR), final mean refractive error (spherical equivalent and astigmatism), and intra- and post-operative complications.
Results:
Overall 17 eyes of 17 patients (55% females, age range from 25 to 63 years) were operated and postoperatively followed with a mean time of 12.5+3.4 weeks. Improvement in visual acuity was registered in all eyes with a mean BCVA of 0.23+0.09 logMAR at the end of the follow up. Mean spherical equivalent was − 1.24 ± 1.50 D and median astigmatic error was −1.25 D cylinder (range from −0.5 to −2D). No intraoperative complications were registered and postoperatively all IOLs remained stable and well centered. None of the eyes had scleral necrosis, cistoid macular edema, retinal detachment or endophthalmitis.
Conclusions:
The double-needle technique is an elegant technique for IOL fixation. It is a simple and minimally invasive method for achieving good IOL and haptic fixation and also excellent postoperative visual results.
Financial Disclosure:
None